Assistant Professor of Medicine, University of Chicago Medicine
Oncology
Dr. Michael Maitland, MD
|
|
Give Review
Michael Maitland works in the field of Oncology. He went to Albert Einstein College of Medicine of Yeshiva University. He over the years received 1 awards: "CMS Meaningful Use Stage 1 Certification". Michael Maitland is also a published MD. He has 41 paper published. The most recent paper is: Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide. He accepts Medicare payments and is registered with Medicare.gov.
Publications
- Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide.
- Identification of a variant in KDR associated with serum VEGFR2 and pharmacodynamics of pazopanib.
- Technical considerations in the development of circulating peptides as pharmacodynamic biomarkers for angiogenesis inhibitors.
- Sorafenib Dose Escalation is Not Uniformly Associated with Blood Pressure Elevations in Normotensive Patients with Advanced Malignancies.
- Institutional Profile: University of Chicago Center for Personalized Therapeutics: research, education and implementation science.
- Evaluation of Food Effect on Pharmacokinetics of Vismodegib in Advanced Solid Tumor Patients.
- Estimation of renal cell Carcinoma treatment effects from disease progression modeling.
- More sound Cancer therapy biomarker development with active noise control.
- Cancer pharmacogenomics: strategies and challenges.
- Personalized treatment of lung Cancer.
- Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors.
- A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension.
- Mycobacterial infection of macrophages results in membrane-permeable phagosomes.
- Comparative genomics Analysis of human sequence variation in the UGT1A gene cluster.
- Analysis of the yield of phase II combination therapy trials in medical oncology.
- Volumes to learn: advancing therapeutics with innovative computed tomography image data Analysis.
- Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors.
- Clinical trials in the era of personalized oncology.
- Sunitinib, hypertension, and heart failure: a model for kinase inhibitor-mediated cardiotoxicity.
- A time to keep and a time to cast away categories of tumor response.
- Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies.
- Kinase inhibition-related adverse events predicted from in vitro kinome and clinical trial data.
- Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors.
- A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group.
- Vascular endothelial growth factor pathway.
- Polymorphisms of adrenergic receptors and the risk of heart failure.
- Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung Cancer.
- Other paradigms: better treatments are identified by better trials: the value of randomized phase II studies.
- Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment.
- Inflammation, growth factors, and pulmonary vascular remodeling.
- Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors.
- Cardiovascular toxicity of new agents.
- Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension.
- Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF-1alpha-Kv1.5 O2-sensing pathway at the intersection of pulmonary hypertension and Cancer.
- Interpreting P values in pharmacogenetic studies: a call for process and perspective.
- Design of phase II Cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung Cancer.
- Terminal ballistics of kinase inhibitors: there are no magic bullets.
- Diffuse alveolar damage after a single dose of topotecan in a patient with pulmonary fibrosis and small cell lung Cancer.
- TPMT, UGT1A1 and DPYD: genotyping to ensure safer Cancer therapy?
- Interpreting disparate responses to Cancer therapy: the role of human population genetics.
Schools
A Einstein Col Med Yeshiva Univ
New York Presbyterian HospitalWeill Cornell Med Center
Meml Sloan Kettering Cancer Center
University Of Chicago Hospitals and Health System
Procedures Preformed
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Bile Duct Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Blue Card PPO
- Blue Cross Blue Shield of Illinois PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Cofinity PPO
- Coventry Health Care of Illinois PPO
- Health and Life PPO
- Platinum PPO
- Coventry Health Care of Missouri PPO
- First Health (Coventry Health Care) PPO
- HealthLink PPO
- MultiPlan PPO
- PHCS Network PPO
- Choice Plus POS
- Options PPO
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
University of Chicago -
New York Presbyterian Hospital -
Albert Einstein College of Medicine of Yeshiva University
Hospital
-
University of Chicago Medical Center
Drug Facts
| NPI NUMBER | 1003851460 | |
| NPPES Provider LastName | MAITLAND | |
| NPPES Provider FirstName | MICHAEL | |
| NPPES Provider ZIPCode | 606371447 | |
| NPPES Provider State | IL | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 35.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1003851460 |
| Last Name Of The Provider | MAITLAND |
| First Name Of The Provider | MICHAEL |
| View All |
Similar Doctors
|
|
Dr. Victoria M. Villaflor, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lily P. Hussein, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John L. Showel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Blase N. Polite, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Fred Rosen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Silviya V. Velinova, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Boris Pasche, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Robert S. Young, MD |
|
|
Dr. Nyambi Ebie, MD
This Doctor is OpenDoctor Recommended.
|